<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016315</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-0017</org_study_id>
    <secondary_id>RTOG-L-0017</secondary_id>
    <secondary_id>CDR0000068622</secondary_id>
    <nct_id>NCT00016315</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Study of Gemcitabine, Carboplatin or Gemcitabine, Paclitaxel and Radiation Therapy Followed by Adjuvant Chemotherapy for Patients With Favorable Prognosis Inoperable Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and paclitaxel, work
      in different ways to stop tumor cells from dividing so they stop growing or die. Radiation
      therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with
      chemotherapy may kill more tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of combining combination chemotherapy with
      radiation therapy in treating patients who have stage IIIA or stage IIIB non-small cell lung
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose (MTD) of gemcitabine when administered with
           carboplatin and thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin
           in patients with stage IIIA or IIIB non-small cell lung cancer.

        -  Determine the MTD of gemcitabine and paclitaxel when administered with thoracic
           radiotherapy followed by adjuvant gemcitabine and carboplatin in these patients.

      OUTLINE: This is a multicenter, dose-escalation study of gemcitabine and paclitaxel. Patients
      are sequentially assigned to 1 of 3 treatment regimens.

        -  Regimen A: Patients receive gemcitabine IV over 30-60 minutes on days 1, 8, 22, 29, and
           43 and thoracic radiotherapy daily 5 days a week for 7 weeks beginning on day 1.

        -  Regimen B (closed to accrual as of 5/13/03): Patients receive gemcitabine and thoracic
           radiotherapy as in regimen A and carboplatin IV over 30 minutes on days 1, 8, 22, 29,
           and 43.

        -  Regimen C: Patients receive gemcitabine and thoracic radiotherapy as in regimen A and
           paclitaxel IV over 1 hour on days 1, 8, 22, 29, and 43.

      At 3 weeks after completion of chemoradiotherapy, all patients receive adjuvant gemcitabine
      IV over 30-60 minutes on days 71, 78, 92, and 99 and carboplatin IV over 30 minutes on days
      71 and 92.

      The first 6 patients enrolled receive regimen A to determine the safety of the initial dose
      of gemcitabine. After completion of regimen A, cohorts of 3-6 patients receive escalating
      doses of gemcitabine in regimen B (closed to accrual as of 5/13/03) until the maximum
      tolerated dose (MTD) is determined. In a separate sequence, cohorts of 3-6 patients receive
      alternating escalating doses of gemcitabine and paclitaxel in regimen C until the MTD is
      determined. The MTD is defined as the dose preceding that at which at least 3 of 6 patients
      experience dose-limiting toxicity.

      Patients are followed at 3 months, 6 months, every 3 months for 1 year, every 6 months for 2
      years, and then annually thereafter.

      PROJECTED ACCRUAL: A maximum of 78 patients will be accrued for this study within 29 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose of gemcitabine with carboplatin-based chemotherapy and radiation therapy</measure>
    <time_frame>From start of treatment to 90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose of gemcitabine with paclitaxel-based chemotherapy and radiation therapy</measure>
    <time_frame>From start of treatment to 90 days</time_frame>
  </primary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence A: Gemcitabine 300 mg/m2/week plus radiation therapy (RT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence B: Gemcitabine 300 mg/m2/week plus paclitaxel 30 mg/m2/week and RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence A: Gemcitabine 300 mg/m2/week plus carboplatin 2 AUC and RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 30 mg/m2/week and RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 40 mg/m2/week and RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 40 mg/m2/week and RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 50 mg/m2/week and RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence B: Gemcitabine 750 mg/m2/week plus paclitaxel 50 mg/m2/week and RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence B: Gemcitabine 900 mg/m2/week plus paclitaxel 50 mg/m2/week and RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence A: Gemcitabine 450 mg/m2/week plus carboplatin 2 AUC and RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence A: Gemcitabine 600 mg/m2/week plus carboplatin 2 AUC and RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence A: Gemcitabine 750 mg/m2/week plus carboplatin 2 AUC and RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence A: Gemcitabine 900 mg/m2/week plus carboplatin 2 AUC and RT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_label>Arm 9</arm_group_label>
    <arm_group_label>Arm 11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_label>Arm 10</arm_group_label>
    <arm_group_label>Arm 12</arm_group_label>
    <arm_group_label>Arm 14</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_label>Arm 9</arm_group_label>
    <arm_group_label>Arm 11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_label>Arm 10</arm_group_label>
    <arm_group_label>Arm 12</arm_group_label>
    <arm_group_label>Arm 14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_label>Arm 10</arm_group_label>
    <arm_group_label>Arm 12</arm_group_label>
    <arm_group_label>Arm 14</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_label>Arm 9</arm_group_label>
    <arm_group_label>Arm 11</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed loco-regionally advanced non-small cell lung
             cancer meeting one of the following staging criteria:

               -  Medically inoperable stage IIIA

               -  Unresectable stage IIIA or IIIB

          -  Measurable disease on three-dimensional planning CT scan

          -  No post-resection intrathoracic tumor recurrence

          -  No pleural effusion on chest x-ray except those occurring after attempted thoracotomy
             or other invasive thoracic procedure

          -  No evidence of small cell histology

          -  No evidence of hematogenous or distant metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  Zubrod 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Platelet count at least 100,000/mm^3

          -  Absolute granulocyte count at least 2,000/mm^3

          -  Hemoglobin at least 8.0 g/dL

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

          -  Serum glutamate oxaloacetate transaminase (SGOT) no greater than 1.5 times upper limit
             of normal (unless caused by documented benign disease)

        Renal:

          -  Creatinine no greater than 1.5 mg/dL

        Cardiovascular:

          -  No myocardial infarction within the past 6 months

          -  No symptomatic heart disease, including angina, congestive heart failure, or
             uncontrolled arrhythmia

        Pulmonary:

          -  Forced expiratory volume (FEV)_1 greater than 1,000 mL

        Other:

          -  No other invasive malignancy within the past 3 years except nonmelanoma skin cancer

          -  No weight loss of more than 10% in 3 months prior to diagnosis

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior thoracic or neck radiotherapy

        Surgery:

          -  See Disease Characteristics

          -  No prior complete or subtotal tumor resection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hak Choy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Bay Area Tumor Institute</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609-3305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wendt Regional Cancer Center of Finley Hospital</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monmouth Medical Center</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740-6395</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center, Incorporated</name>
      <address>
        <city>Salem</city>
        <state>Ohio</state>
        <zip>44460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware County Memorial Hospital</name>
      <address>
        <city>Drexel Hill</city>
        <state>Pennsylvania</state>
        <zip>19026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dale and Frances Hughes Cancer Center</name>
      <address>
        <city>East Stroudsburg</city>
        <state>Pennsylvania</state>
        <zip>18301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-5671</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cottonwood Hospital Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKay-Dee Hospital Center</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Regional Medical Center - Provo</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dixie Regional Medical Center</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danville Regional Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Milwaukee (Zablocki)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Choy H, Jain AK, Moughan J, Curran W, Whipple G, Demas WF, Ettinger DS. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy (&quot;ping-pong trial&quot;) followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. J Thorac Oncol. 2009 Jan;4(1):80-6. doi: 10.1097/JTO.0b013e318191503f.</citation>
    <PMID>19096311</PMID>
  </results_reference>
  <results_reference>
    <citation>Choy H, Swann S, Curran W, et al.: A phase I trial of gemcitabine, carboplatin or gemcitabine, paclitaxel and concurrent radiation therapy followed by consolidative gemcitabine and carboplatin for inoperable stage III non-small cell lung cancer: an RTOG 0017 study. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-70, S42, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Choy H, Swann S, Walter C, et al.: A phase I trial of gemcitabine, carboplatin or gemcitabine, paclitaxel and concurrent radiation therapy followed by consolidative gemcitabine and carboplatin for inoperable stage III non-small cell lung cancer: an RTOG study. [Abstract] J Clin Oncol 23 (Suppl 16): A-7103, 646s, 2005.</citation>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>November 14, 2015</last_update_submitted>
  <last_update_submitted_qc>November 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

